Filing Flows › Health Care › Nexalin Technology (NXL)
Nexalin Technology (NXL) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Nexalin Technology (NXL) Q2 2026 earnings results →
Q2 2026 Revenue down 83% year over year to $12K
Nexalin Technology made $12K in Q2 2026 (-83% Y/Y). Operating margin n/m, net loss $2.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $12K in Q2 2026, down 83% year over year and down 19% from the previous quarter.
Gross margin was 73.2%, up 5.5 points from Q2 2025. Operating costs exceeded revenue by $2.2M, an operating margin of -18479.7%. Operating expenses grew 35% against a revenue fall of 83%. The fastest-growing cost line was Research & development (+150%). The quarter ended with a net loss of $2.2M, wider than the previous quarter's $2.1M loss.
Operating cash flow was −$1.8M. Non-cash charges added back $9K of depreciation and amortization and $408K of share-based compensation.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $12K | -83% | n/m | −$2.2M | −$1.8M |
| Q1 2026 | 10-Q | May 8, 2026 | $15K | -64% | n/m | −$2.1M | −$1.7M |
| Q4 2025 | 10-K | Mar 25, 2026 | $172K | +532% | n/m | −$2.4M | −$1.1M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $18K | -50% | n/m | −$2.3M | −$1.5M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $71K | +163% | n/m | −$1.6M | −$917K |
| Q1 2025 | 10-Q | May 13, 2025 | $41K | -48% | n/m | −$2.0M | −$1.4M |
| Q4 2024 | 10-K | Mar 14, 2025 | $27K | +32% | n/m | −$2.8M | −$1.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Nexalin Technology
Nexalin is headquartered, and maintains its base of management and operations, in Houston, Texas. We design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as “Generation 1” or “Gen-1” — that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (the “FDA”) as a Class II device.
In its own words, from its 10-K, filed Mar 25, 2026.
Nexalin Technology against its Electromedical & Electrotherapeutic Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -83% against the peers' median +14%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NXL Nexalin Technology | Q2 2026 | $12K | -83% | n/m |
| MDT Medtronic | Q1 FY27 | $9.8B | +14% | 18.1% |
| ITGR Integer Holdings | Q3 2026 | $450M | -4% | 6.3% |
| LIVN LivaNova | Q3 2026 | $393M | +10% | 7.2% |
| CNMD Conmed | Q3 2026 | $336M | -0.7% | 11.1% |
| TMDX TransMedics Group | Q3 2026 | $203M | +41% | 13.9% |
| AXGN Axogen | Q3 2026 | $75.8M | +26% | 1.3% |
| OM Outset Medical | Q3 2026 | $33.6M | +14% | -36.5% |
| CBLL Ceribell | Q3 2026 | $29.3M | +30% | -70.0% |
Source: Nexalin Technology 10-Q on SEC EDGAR · CIK 1527352 · Electromedical & Electrotherapeutic Apparatus
More on NXL
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results